Report cover image

Global Antisense Oligonucleotide Therapies Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 197 Pages
SKU # APRC20360136

Description

Summary

According to APO Research, the global Antisense Oligonucleotide Therapies market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Antisense Oligonucleotide Therapies is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % from 2025 through 2031.

The Asia-Pacific market for Antisense Oligonucleotide Therapies is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Antisense Oligonucleotide Therapies market is expected to rise from $ million to $ million by 2031, at a CAGR of I% from 2025 through 2031.

The Europe market for Antisense Oligonucleotide Therapies is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Antisense Oligonucleotide Therapies market include Sarepta Therapeutics, Nippon Shinyaku and Ionis Pharmaceuticals, etc. In 2024, the top three vendors accounted for approximately % of the market revenue.

This report presents an overview of global market for Antisense Oligonucleotide Therapies, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Antisense Oligonucleotide Therapies, also provides the value of main regions and countries. Of the upcoming market potential for Antisense Oligonucleotide Therapies, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Antisense Oligonucleotide Therapies revenue, market share and industry ranking of main companies, data from 2020 to 2025. Identification of the major stakeholders in the global Antisense Oligonucleotide Therapies market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global Antisense Oligonucleotide Therapies company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
Antisense Oligonucleotide Therapies Segment by Company

Sarepta Therapeutics
Nippon Shinyaku
Ionis Pharmaceuticals
Antisense Oligonucleotide Therapies Segment by Type

Without GalNAc-conjugated
With GalNAc-conjugated
Antisense Oligonucleotide Therapies Segment by Application

Cancer
Cardiovascular Diseases
Genetic Disease
Other
Antisense Oligonucleotide Therapies Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global Antisense Oligonucleotide Therapies status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Antisense Oligonucleotide Therapies key companies, revenue, market share, and recent developments.
3. To split the Antisense Oligonucleotide Therapies breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Antisense Oligonucleotide Therapies market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Antisense Oligonucleotide Therapies significant trends, drivers, influence factors in global and regions.
6. To analyze Antisense Oligonucleotide Therapies competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antisense Oligonucleotide Therapies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Antisense Oligonucleotide Therapies and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antisense Oligonucleotide Therapies.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Antisense Oligonucleotide Therapies industry.
Chapter 3: Detailed analysis of Antisense Oligonucleotide Therapies company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Antisense Oligonucleotide Therapies in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Antisense Oligonucleotide Therapies in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.

Table of Contents

197 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Antisense Oligonucleotide Therapies Market Size, 2020 VS 2024 VS 2031
1.3 Global Antisense Oligonucleotide Therapies Market Size (2020-2031)
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Antisense Oligonucleotide Therapies Market Dynamics
2.1 Antisense Oligonucleotide Therapies Industry Trends
2.2 Antisense Oligonucleotide Therapies Industry Drivers
2.3 Antisense Oligonucleotide Therapies Industry Opportunities and Challenges
2.4 Antisense Oligonucleotide Therapies Industry Restraints
3 Antisense Oligonucleotide Therapies Market by Company
3.1 Global Antisense Oligonucleotide Therapies Company Revenue Ranking in 2024
3.2 Global Antisense Oligonucleotide Therapies Revenue by Company (2020-2025)
3.3 Global Antisense Oligonucleotide Therapies Company Ranking (2023-2025)
3.4 Global Antisense Oligonucleotide Therapies Company Manufacturing Base and Headquarters
3.5 Global Antisense Oligonucleotide Therapies Company Product Type and Application
3.6 Global Antisense Oligonucleotide Therapies Company Establishment Date
3.7 Market Competitive Analysis
3.7.1 Global Antisense Oligonucleotide Therapies Market Concentration Ratio (CR5 and HHI)
3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.7.3 2024 Antisense Oligonucleotide Therapies Tier 1, Tier 2, and Tier 3 Companies
3.8 Mergers and Acquisitions Expansion
4 Antisense Oligonucleotide Therapies Market by Type
4.1 Antisense Oligonucleotide Therapies Type Introduction
4.1.1 Without GalNAc-conjugated
4.1.2 With GalNAc-conjugated
4.2 Global Antisense Oligonucleotide Therapies Sales Value by Type
4.2.1 Global Antisense Oligonucleotide Therapies Sales Value by Type (2020 VS 2024 VS 2031)
4.2.2 Global Antisense Oligonucleotide Therapies Sales Value by Type (2020-2031)
4.2.3 Global Antisense Oligonucleotide Therapies Sales Value Share by Type (2020-2031)
5 Antisense Oligonucleotide Therapies Market by Application
5.1 Antisense Oligonucleotide Therapies Application Introduction
5.1.1 Cancer
5.1.2 Cardiovascular Diseases
5.1.3 Genetic Disease
5.1.4 Other
5.2 Global Antisense Oligonucleotide Therapies Sales Value by Application
5.2.1 Global Antisense Oligonucleotide Therapies Sales Value by Application (2020 VS 2024 VS 2031)
5.2.2 Global Antisense Oligonucleotide Therapies Sales Value by Application (2020-2031)
5.2.3 Global Antisense Oligonucleotide Therapies Sales Value Share by Application (2020-2031)
6 Antisense Oligonucleotide Therapies Regional Value Analysis
6.1 Global Antisense Oligonucleotide Therapies Sales Value by Region: 2020 VS 2024 VS 2031
6.2 Global Antisense Oligonucleotide Therapies Sales Value by Region (2020-2031)
6.2.1 Global Antisense Oligonucleotide Therapies Sales Value by Region: 2020-2025
6.2.2 Global Antisense Oligonucleotide Therapies Sales Value by Region (2026-2031)
6.3 North America
6.3.1 North America Antisense Oligonucleotide Therapies Sales Value (2020-2031)
6.3.2 North America Antisense Oligonucleotide Therapies Sales Value Share by Country, 2024 VS 2031
6.4 Europe
6.4.1 Europe Antisense Oligonucleotide Therapies Sales Value (2020-2031)
6.4.2 Europe Antisense Oligonucleotide Therapies Sales Value Share by Country, 2024 VS 2031
6.5 Asia-Pacific
6.5.1 Asia-Pacific Antisense Oligonucleotide Therapies Sales Value (2020-2031)
6.5.2 Asia-Pacific Antisense Oligonucleotide Therapies Sales Value Share by Country, 2024 VS 2031
6.6 South America
6.6.1 South America Antisense Oligonucleotide Therapies Sales Value (2020-2031)
6.6.2 South America Antisense Oligonucleotide Therapies Sales Value Share by Country, 2024 VS 2031
6.7 Middle East & Africa
6.7.1 Middle East & Africa Antisense Oligonucleotide Therapies Sales Value (2020-2031)
6.7.2 Middle East & Africa Antisense Oligonucleotide Therapies Sales Value Share by Country, 2024 VS 2031
7 Antisense Oligonucleotide Therapies Country-level Value Analysis
7.1 Global Antisense Oligonucleotide Therapies Sales Value by Country: 2020 VS 2024 VS 2031
7.2 Global Antisense Oligonucleotide Therapies Sales Value by Country (2020-2031)
7.2.1 Global Antisense Oligonucleotide Therapies Sales Value by Country (2020-2025)
7.2.2 Global Antisense Oligonucleotide Therapies Sales Value by Country (2026-2031)
7.3 USA
7.3.1 USA Antisense Oligonucleotide Therapies Sales Value Growth Rate (2020-2031)
7.3.2 USA Antisense Oligonucleotide Therapies Sales Value Share by Type, 2024 VS 2031
7.3.3 USA Antisense Oligonucleotide Therapies Sales Value Share by Application, 2024 VS 2031
7.4 Canada
7.4.1 Canada Antisense Oligonucleotide Therapies Sales Value Growth Rate (2020-2031)
7.4.2 Canada Antisense Oligonucleotide Therapies Sales Value Share by Type, 2024 VS 2031
7.4.3 Canada Antisense Oligonucleotide Therapies Sales Value Share by Application, 2024 VS 2031
7.5 Mexico
7.5.1 Mexico Antisense Oligonucleotide Therapies Sales Value Growth Rate (2020-2031)
7.5.2 Mexico Antisense Oligonucleotide Therapies Sales Value Share by Type, 2024 VS 2031
7.5.3 Mexico Antisense Oligonucleotide Therapies Sales Value Share by Application, 2024 VS 2031
7.6 Germany
7.6.1 Germany Antisense Oligonucleotide Therapies Sales Value Growth Rate (2020-2031)
7.6.2 Germany Antisense Oligonucleotide Therapies Sales Value Share by Type, 2024 VS 2031
7.6.3 Germany Antisense Oligonucleotide Therapies Sales Value Share by Application, 2024 VS 2031
7.7 France
7.7.1 France Antisense Oligonucleotide Therapies Sales Value Growth Rate (2020-2031)
7.7.2 France Antisense Oligonucleotide Therapies Sales Value Share by Type, 2024 VS 2031
7.7.3 France Antisense Oligonucleotide Therapies Sales Value Share by Application, 2024 VS 2031
7.8 U.K.
7.8.1 U.K. Antisense Oligonucleotide Therapies Sales Value Growth Rate (2020-2031)
7.8.2 U.K. Antisense Oligonucleotide Therapies Sales Value Share by Type, 2024 VS 2031
7.8.3 U.K. Antisense Oligonucleotide Therapies Sales Value Share by Application, 2024 VS 2031
7.9 Italy
7.9.1 Italy Antisense Oligonucleotide Therapies Sales Value Growth Rate (2020-2031)
7.9.2 Italy Antisense Oligonucleotide Therapies Sales Value Share by Type, 2024 VS 2031
7.9.3 Italy Antisense Oligonucleotide Therapies Sales Value Share by Application, 2024 VS 2031
7.10 Spain
7.10.1 Spain Antisense Oligonucleotide Therapies Sales Value Growth Rate (2020-2031)
7.10.2 Spain Antisense Oligonucleotide Therapies Sales Value Share by Type, 2024 VS 2031
7.10.3 Spain Antisense Oligonucleotide Therapies Sales Value Share by Application, 2024 VS 2031
7.11 Russia
7.11.1 Russia Antisense Oligonucleotide Therapies Sales Value Growth Rate (2020-2031)
7.11.2 Russia Antisense Oligonucleotide Therapies Sales Value Share by Type, 2024 VS 2031
7.11.3 Russia Antisense Oligonucleotide Therapies Sales Value Share by Application, 2024 VS 2031
7.12 Netherlands
7.12.1 Netherlands Antisense Oligonucleotide Therapies Sales Value Growth Rate (2020-2031)
7.12.2 Netherlands Antisense Oligonucleotide Therapies Sales Value Share by Type, 2024 VS 2031
7.12.3 Netherlands Antisense Oligonucleotide Therapies Sales Value Share by Application, 2024 VS 2031
7.13 Nordic Countries
7.13.1 Nordic Countries Antisense Oligonucleotide Therapies Sales Value Growth Rate (2020-2031)
7.13.2 Nordic Countries Antisense Oligonucleotide Therapies Sales Value Share by Type, 2024 VS 2031
7.13.3 Nordic Countries Antisense Oligonucleotide Therapies Sales Value Share by Application, 2024 VS 2031
7.14 China
7.14.1 China Antisense Oligonucleotide Therapies Sales Value Growth Rate (2020-2031)
7.14.2 China Antisense Oligonucleotide Therapies Sales Value Share by Type, 2024 VS 2031
7.14.3 China Antisense Oligonucleotide Therapies Sales Value Share by Application, 2024 VS 2031
7.15 Japan
7.15.1 Japan Antisense Oligonucleotide Therapies Sales Value Growth Rate (2020-2031)
7.15.2 Japan Antisense Oligonucleotide Therapies Sales Value Share by Type, 2024 VS 2031
7.15.3 Japan Antisense Oligonucleotide Therapies Sales Value Share by Application, 2024 VS 2031
7.16 South Korea
7.16.1 South Korea Antisense Oligonucleotide Therapies Sales Value Growth Rate (2020-2031)
7.16.2 South Korea Antisense Oligonucleotide Therapies Sales Value Share by Type, 2024 VS 2031
7.16.3 South Korea Antisense Oligonucleotide Therapies Sales Value Share by Application, 2024 VS 2031
7.17 India
7.17.1 India Antisense Oligonucleotide Therapies Sales Value Growth Rate (2020-2031)
7.17.2 India Antisense Oligonucleotide Therapies Sales Value Share by Type, 2024 VS 2031
7.17.3 India Antisense Oligonucleotide Therapies Sales Value Share by Application, 2024 VS 2031
7.18 Australia
7.18.1 Australia Antisense Oligonucleotide Therapies Sales Value Growth Rate (2020-2031)
7.18.2 Australia Antisense Oligonucleotide Therapies Sales Value Share by Type, 2024 VS 2031
7.18.3 Australia Antisense Oligonucleotide Therapies Sales Value Share by Application, 2024 VS 2031
7.19 Southeast Asia
7.19.1 Southeast Asia Antisense Oligonucleotide Therapies Sales Value Growth Rate (2020-2031)
7.19.2 Southeast Asia Antisense Oligonucleotide Therapies Sales Value Share by Type, 2024 VS 2031
7.19.3 Southeast Asia Antisense Oligonucleotide Therapies Sales Value Share by Application, 2024 VS 2031
7.20 Brazil
7.20.1 Brazil Antisense Oligonucleotide Therapies Sales Value Growth Rate (2020-2031)
7.20.2 Brazil Antisense Oligonucleotide Therapies Sales Value Share by Type, 2024 VS 2031
7.20.3 Brazil Antisense Oligonucleotide Therapies Sales Value Share by Application, 2024 VS 2031
7.21 Argentina
7.21.1 Argentina Antisense Oligonucleotide Therapies Sales Value Growth Rate (2020-2031)
7.21.2 Argentina Antisense Oligonucleotide Therapies Sales Value Share by Type, 2024 VS 2031
7.21.3 Argentina Antisense Oligonucleotide Therapies Sales Value Share by Application, 2024 VS 2031
7.22 Chile
7.22.1 Chile Antisense Oligonucleotide Therapies Sales Value Growth Rate (2020-2031)
7.22.2 Chile Antisense Oligonucleotide Therapies Sales Value Share by Type, 2024 VS 2031
7.22.3 Chile Antisense Oligonucleotide Therapies Sales Value Share by Application, 2024 VS 2031
7.23 Colombia
7.23.1 Colombia Antisense Oligonucleotide Therapies Sales Value Growth Rate (2020-2031)
7.23.2 Colombia Antisense Oligonucleotide Therapies Sales Value Share by Type, 2024 VS 2031
7.23.3 Colombia Antisense Oligonucleotide Therapies Sales Value Share by Application, 2024 VS 2031
7.24 Peru
7.24.1 Peru Antisense Oligonucleotide Therapies Sales Value Growth Rate (2020-2031)
7.24.2 Peru Antisense Oligonucleotide Therapies Sales Value Share by Type, 2024 VS 2031
7.24.3 Peru Antisense Oligonucleotide Therapies Sales Value Share by Application, 2024 VS 2031
7.25 Saudi Arabia
7.25.1 Saudi Arabia Antisense Oligonucleotide Therapies Sales Value Growth Rate (2020-2031)
7.25.2 Saudi Arabia Antisense Oligonucleotide Therapies Sales Value Share by Type, 2024 VS 2031
7.25.3 Saudi Arabia Antisense Oligonucleotide Therapies Sales Value Share by Application, 2024 VS 2031
7.26 Israel
7.26.1 Israel Antisense Oligonucleotide Therapies Sales Value Growth Rate (2020-2031)
7.26.2 Israel Antisense Oligonucleotide Therapies Sales Value Share by Type, 2024 VS 2031
7.26.3 Israel Antisense Oligonucleotide Therapies Sales Value Share by Application, 2024 VS 2031
7.27 UAE
7.27.1 UAE Antisense Oligonucleotide Therapies Sales Value Growth Rate (2020-2031)
7.27.2 UAE Antisense Oligonucleotide Therapies Sales Value Share by Type, 2024 VS 2031
7.27.3 UAE Antisense Oligonucleotide Therapies Sales Value Share by Application, 2024 VS 2031
7.28 Turkey
7.28.1 Turkey Antisense Oligonucleotide Therapies Sales Value Growth Rate (2020-2031)
7.28.2 Turkey Antisense Oligonucleotide Therapies Sales Value Share by Type, 2024 VS 2031
7.28.3 Turkey Antisense Oligonucleotide Therapies Sales Value Share by Application, 2024 VS 2031
7.29 Iran
7.29.1 Iran Antisense Oligonucleotide Therapies Sales Value Growth Rate (2020-2031)
7.29.2 Iran Antisense Oligonucleotide Therapies Sales Value Share by Type, 2024 VS 2031
7.29.3 Iran Antisense Oligonucleotide Therapies Sales Value Share by Application, 2024 VS 2031
7.30 Egypt
7.30.1 Egypt Antisense Oligonucleotide Therapies Sales Value Growth Rate (2020-2031)
7.30.2 Egypt Antisense Oligonucleotide Therapies Sales Value Share by Type, 2024 VS 2031
7.30.3 Egypt Antisense Oligonucleotide Therapies Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Sarepta Therapeutics
8.1.1 Sarepta Therapeutics Comapny Information
8.1.2 Sarepta Therapeutics Business Overview
8.1.3 Sarepta Therapeutics Antisense Oligonucleotide Therapies Revenue and Gross Margin (2020-2025)
8.1.4 Sarepta Therapeutics Antisense Oligonucleotide Therapies Product Portfolio
8.1.5 Sarepta Therapeutics Recent Developments
8.2 Nippon Shinyaku
8.2.1 Nippon Shinyaku Comapny Information
8.2.2 Nippon Shinyaku Business Overview
8.2.3 Nippon Shinyaku Antisense Oligonucleotide Therapies Revenue and Gross Margin (2020-2025)
8.2.4 Nippon Shinyaku Antisense Oligonucleotide Therapies Product Portfolio
8.2.5 Nippon Shinyaku Recent Developments
8.3 Ionis Pharmaceuticals
8.3.1 Ionis Pharmaceuticals Comapny Information
8.3.2 Ionis Pharmaceuticals Business Overview
8.3.3 Ionis Pharmaceuticals Antisense Oligonucleotide Therapies Revenue and Gross Margin (2020-2025)
8.3.4 Ionis Pharmaceuticals Antisense Oligonucleotide Therapies Product Portfolio
8.3.5 Ionis Pharmaceuticals Recent Developments
9 Concluding Insights
10 Appendix
10.1 Reasons for Doing This Study
10.2 Research Methodology
10.3 Research Process
10.4 Authors List of This Report
10.5 Data Source
10.5.1 Secondary Sources
10.5.2 Primary Sources
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.